Víctor Cervera-Carrascón
M.Pharm, Head of Immunology
Head of Immunology, Víctor Cervera-Carrascón, has expertise in immunotherapy, particularly on the use of oncolytic viruses to enable immune checkpoint blockade and other T-cell related approaches. Victor is completing a PhD from the Marie Skłodowska-Curie consortium (Netherlands and Finland) in oncolytic viruses. Victor is responsible for, in particular, work with oncolytic viruses and checkpoint inhibitors and is translating preclinical success into clinical trials, as well as supporting business development.
